|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5756508A
(en)
|
1995-10-31 |
1998-05-26 |
Merck & Co., Inc. |
Muscarine antagonists
|
|
DE69839355T2
(de)
|
1997-07-29 |
2009-06-04 |
Alcon Laboratories, Inc., Fort Worth |
Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
|
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
EP1654002B2
(en)
|
2003-08-07 |
2014-01-29 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
GB0403635D0
(en)
*
|
2004-02-18 |
2004-03-24 |
Devgen Nv |
Pyridinocarboxamides with improved activity as kinase inhibitors
|
|
US8211919B2
(en)
*
|
2005-09-02 |
2012-07-03 |
Astellas Pharma Inc. |
Amide derivatives as rock inhibitors
|
|
CN101678215B
(zh)
*
|
2007-04-18 |
2014-10-01 |
辉瑞产品公司 |
用于治疗异常细胞生长的磺酰胺衍生物
|
|
EP3828172A1
(en)
*
|
2009-05-01 |
2021-06-02 |
Aerie Pharmaceuticals, Inc. |
Dual mechanism inhibitors for the treatment of disease
|
|
GB201106817D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2016198908A1
(en)
|
2015-06-09 |
2016-12-15 |
Abbvie Inc. |
Ror nuclear receptor modulators
|
|
AU2017253560B2
(en)
*
|
2016-04-20 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Conjugates comprising RIPK2 inhibitors
|
|
WO2017194390A1
(en)
*
|
2016-05-09 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Dimeric compounds
|
|
US20210283261A1
(en)
*
|
2017-12-05 |
2021-09-16 |
Icahn School Of Medicine At Mount Sinai |
Compositions and Methods for Treating ALK-Mediated Cancer
|
|
US20240408106A1
(en)
*
|
2021-09-13 |
2024-12-12 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
US11981672B2
(en)
*
|
2021-09-13 |
2024-05-14 |
Montelino Therapeutics Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|